Abstract
Glycoprotein IIb/IIIa inhibitors reduce ischemic complications during percutaneous coronary intervention (PCI). However, in the partially industry-supported ISAR-REACT trial (Journal Watch Cardiology Feb 27 2004), abciximab did not add benefit to clopidogrel pretreatment in low- and intermediate-risk patients undergoing elective PCI. What about in high-risk …
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have